- Date 05 May 2010
- Documents : 3
- (Restricted access link)
- History
Listen
Reason for request
Inclusion on the list of medicines reimbursed by National Health Insurance and approved for hospital use in the extension of indication “”Monotherapy treatment for typical absence seizures in children and adolescents aged 2 to 12 years”.
-
Clinical Benefit
| Substantial |
The actual benefit of these medicinal products is substantial. |
Clinical Added Value
| no clinical added value |
LAMICTAL and LAMICSTART do not provide an improvement in actual benefit (IAB V) in the management by monotherapy of typical absence seizures in children and adolescents aged 2 to 12 years. |
English version
Contact Us
Évaluation des médicaments
